Repligen Corp (RGEN)

[surf1944]

7:36AM Repligen reports Q1 results, revs rose 28% YoY to $16.5 mln, provides guidance for 2013 (RGEN) 8.68 : Co reports Q1 EPS of $0.07 vs $0.04 in the year ago period. Revenue rose 28.3% YoY to $16.5 mln. There are no analyst estimates. Bioprocessing product revenue for Q1 was $11.9 mln, a 28% YoY increase. Total revenue for the full year 2013 is expected to be $63-$65 mln, including the receipt of royalties from Bristol-Myers Squibb on its US sales of Orencia, which the co will no longer receive after December 31, 2013. Bioprocessing product revenue for 2013 is expected to be $46-$48 mln, reflecting product sales growth of 10%-15%. Net income for the full year 2013 is expected to be $18-$20 mln.